8-N-[(1R)-1-phenylpropyl]-6-N-(pyrazin-2-ylmethyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-6,8-dicarboxamide
C23H25N5O3 — CID 71695683
Data last refreshed: (MolForge compound catalog, from PubChem)
About 8-N-[(1R)-1-phenylpropyl]-6-N-(pyrazin-2-ylmethyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-6,8-dicarboxamide
8-N-[(1R)-1-phenylpropyl]-6-N-(pyrazin-2-ylmethyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-6,8-dicarboxamide (PubChem CID 71695683) has the molecular formula C23H25N5O3 and a molecular weight of 419.49 g/mol. Its IUPAC name is 8-N-[(1R)-1-phenylpropyl]-6-N-(pyrazin-2-ylmethyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-6,8-dicarboxamide.
Molecular Properties
| Compound Name | 8-N-[(1R)-1-phenylpropyl]-6-N-(pyrazin-2-ylmethyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-6,8-dicarboxamide |
|---|---|
| PubChem CID | 71695683 |
| Molecular Formula | C23H25N5O3 |
| Molecular Weight | 419.49 g/mol |
| Exact Mass | 419.20 |
| IUPAC Name | 8-N-[(1R)-1-phenylpropyl]-6-N-(pyrazin-2-ylmethyl)-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-6,8-dicarboxamide |
| SMILES | CC[C@@H](NC(=O)c1cc(C(=O)NCc2cnccn2)n2c1COCC2)c1ccccc1 |
| InChI | InChI=1S/C23H25N5O3/c1-2-19(16-6-4-3-5-7-16)27-22(29)18-12-20(28-10-11-31-15-21(18)28)23(30)26-14-17-13-24-8-9-25-17/h3-9,12-13,19H,2,10-11,14-15H2,1H3,(H,26,30)(H,27,29)/t19-/m1/s1 |
| InChIKey | MMFXNOOHGYIWRB-LJQANCHMSA-N |
| XLogP | 2.62 |
| TPSA | 98.14 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 419.49 |
| LogP ≤ 5 | 2.62 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 71695683 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.